Loading...
 
Mediterr J Rheumatol 2017;28(1):27-42
Pan Arab Osteoporosis Society Guidelines for Osteoporosis Management
Authors Information

1: Iraqi Osteoporosis Society

2: Syrian National Osteoporosis Society

3: Moroccan Society for Rheumatology

4: Emirates Osteoporosis Society

5: Egyptian Osteoporosis Prevention Society

6: Jordanian Physicians Osteoporosis Society

7: Jordanian Osteoporosis Prevention Society

8: Palestinian Osteoporosis Prevention Society

9: Lebanese Osteoporosis Prevention Society

10: Bahrain Osteoporosis Society

11: Libyan Osteoporosis Prevention Society

12: Tunisian Osteoporosis Prevention Society

13: Kuwaiti Osteoporosis Society

14: Saudi Osteoporosis Society

15: Hamad Medical Corporation
References
  1. Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD).
  2. Johnell O, Kanis J A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726.
  3. Gullberg B, Johnell O, Kanis J A. World-wide projections for hip fracture. Osteoporos Int 1997;7:407.
  4. Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation. http://nof.org/hcp/resources/913. Accessed Nov. 20, 2014.
  5. Kanis J A, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005;16:581.
  6. NOF's New Clinician's Guide to Prevention and Treatment of Osteoporosis. http://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf (Accessed on January 10, 2011).
  7. The Internationals Society for Clinical Densitometry Official Positions. www.iscd.org/Visitors/positions/OfficialPositionsText.cfm (Accessed on January 10, 2011).
  8. Lewiecki E M, Gordon C M, Baim S, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 2008;43:1115.
  9. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2010. www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf  (Accessed on June 14, 2012).
  10. The International Society for Clinical Densitometry. Official positions. www.iscd.org/Visitors/positions/OfficialPositionsText.cfm (Accessed on June 01, 2008).
  11. International Society for Clinical Densitometry. 2013 Official Positions—Adult. http://www.iscd.org/official-positions/2013-iscd-official-positions-adult/. Accessed Feb 2014.
  12. Osteoporosis: diagnosis, treatment and fracture prevention [Internet]. Vancouver (BC): British Columbia Medical Services Commission; 2011 May 1 [revised 2012 Oct 1; cited 2015 Mar 3].
  13. Gourlay M L, Fine J P, Preisser J S, May R C, Li C, Liu L Y, et al. Study of Osteoporotic Fracture Research Group. Bone-density testing interval and transition to osteoporosis in older women. N Eng J Med 2012;366:225-33.
  14. Kanis J A, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001;12:417.
  15. Baim S, Binkley N, Bilezikian J P, et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008;11:75.
  16. Kanis J A, on behalf of the World Health Organization Scientific Group (2007). Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. 2007: Printed by the University of Sheffield. www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf (Accessed on November 02, 2010).
  17. Writing Group for the ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women, and children. J Clin Densitom 2004;7:17.
  18. Kanis J A, McCloskey E V, Johansson H, et al. A reference standard for the description of osteoporosis. Bone 2008;42:467.
  19. Baim S, Leonard M B, Bianchi M L, et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom 2008;11:6.
  20. Kanis J A, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385.
  21.  WHO Fracture Risk Assessment Tool (FRAX). www.shef.ac.uk/FRAX (Accessed on June 05, 2012).
  22. Hodgson S F, Watts N B, Bilezikian J P, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544.
  23.  Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002;87:4431.
  24. Lewiecki E M, Watts N B, McClung M R, et al. Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab 2004;89:3651.
  25. Institute of Medicine. Report at a Glance, Report Brief: Dietary Reference Intakes for Calcium and Vitamin D, released 11/30/2010.
  26. Granacher U, Gollhofer A, Hortobágyi T, Kressig R W, Muehlbauer T. The importance of trunk muscle strength for balance, functional performance and fall prevention in seniors: a systematic review. Sports Med 2013;43:627-641.
  27.  Sherrington C, Whitney J C, Lord S R, Herbert R D, Cumming R G, Close J C. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc 2008;56:2234-43.
  28.  Choi M, Hector M. Effectiveness of intervention programs in preventing falls: a systematic review of recent 10 years and meta-analysis. J Am Med Dir Assoc 2012;13:188.13-21. 
  29. Ayo-Yusuf O A, Olutola B G. Epidemiological association between osteoporosis and combined smoking and use of snuff among South African women. Niger J Clin Pract 2014;17:174-7.
  30. Waugh E J, Lam M A, Hawker G A, McGowan J, Papaioannou A, Cheung A M, et al. Risk factors for low bone mass in healthy 40-60 year old women: A systematic review of the literature. Osteoporos Int 2009;20:1-21. 
  31. Mikosch P. Alcohol and bone. Wien Med Wochenschr 2014;164:15-24. 
  32. National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. www.nof.org/sites/default/files/pdfs/NOF_Clinicians_Guide2008
  33. Hough S, Evans B H A, Brown S L, et al. NOFSA Guideline for the Diagnosis and Management of Osteoporosis. JEMDSA 2010;15(3).
  34. Tucci J R, Tonino R P, Emkey R D, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488.
  35. Black D M, Cummings S R, Karpf D B, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535.
  36.  Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508.
  37. Bone H G, Hosking D, Devogelaer J P, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189.
  38. Heaney R P, Zizic T M, Fogelman I, et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002;13:501.
  39. Harris S T, Watts N B, Genant H K, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344.
  40. Sorensen O H, Crawford G M, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120.
  41. Chesnut III C H, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241.
  42. Pyon E Y. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Clin Ther 2006;28:475.
  43. US Food and Drug Administration. Highlights of prescribing information - Boniva. www.accessdata.fda.gov/drugsatfda_docs/label/2011/021455s011lbl.pdf (Accessed on March 29, 2012).
  44. Reginster J Y, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654.
  45. Lyles K W, Colón-Emeric C S, Magaziner J S, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799.
  46. Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int 2015 Oct;26:2479-89.
  47. Leder B Z, Tsai J N, Neer R M, et al. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. J Clin Densitom. 2016 Jul-Sep;19:346-51.
  48. Leder B Z, Tsai J N, Uihlein A V, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015;386:1147-55.
  49. Cauley J A, Norton L, Lippman M E, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-134.
  50. Martino S, Cauley, J A, Barrett-Connor E, et alCORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst2004;96:1751-61. 
  51. Chen J F, Yang K H, Zhang Z L, et al. A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia. Osteoporos Int 2015 Jan;26:11-28. https://doi.org/10.1007/s00198-014-2838-7.
  52. Harvey N C, Kanis J A, Odén A, et al. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporos Int. 2015 Sep;26:2347-53.
  53. Binkley N, Bilezikian J P, Kendler D L, et al. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 2006;9:4.
  54. Grossman J M, Gordon R, Ranganath V K, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515.
  55. Saag K G, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028.
  56. Langdahl B L, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009;20:2095.
  57. Fuleihan G-H, Salamoun M, Mourad Y A, et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005;90:3209.
  58. Greenspan S L, Bhattacharya R K, Sereika S M, et al. Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2007;92:131.
  59.  Vehmanen L, Saarto T, Risteli J, et al. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 2004;87:181.
  60.  Watts N B, Adler R A, Bilezikian J P, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:1802.
  61. Zelissen P M, Croughs R J, van Rijk P P, Raymakers J A. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994;120:207.
  62. www.rcplondon.ac.uk/pubs/books/glucocorticoid (Accessed on January 17, 2011).